Abivax Shares Climb 5.55% in Chicago During Digestive Disease Week
The French biotech progresses to €101.80 in mid-session on Monday, marking a 5.55% increase from the last close of €96.45. The movement occurs during the Digestive Disease Week held in Chicago until May 5. The year-over-year performance remains exceptional at +1469%.
The Stock Rebounds During the Chicago Scientific Congress
Abivax advances 5.55% in session to €101.80, while the CAC 40 drops 0.49% at the same time. The rebound takes place during the Digestive Disease Week, where the company presents nine scientific abstracts dedicated to obefazimod, its candidate treatment for ulcerative colitis. These presentations cover the efficacy, tolerance, and patient feedback from the phase 3 ABTECT program, as well as preclinical models of antifibrotic activity. The stock had dropped 2.93% last Wednesday to €92.75 as the event approached. Financially, the company indicated in its third quarter 2025 release that it had cash visibility until the fourth quarter of 2027, following an ADS offering that extended its financial autonomy.
The Stock Returns to Its 50-Day Moving Average
The price is almost at its 50-day moving average of €102.08, after having dipped below it at the end of April. The 200-day moving average at €86.54 remains well below the current price, confirming the underlying bullish trend. The RSI at 42 indicates a market without directional excess, contrasting with the volatility measured at 56.21 over a month. Within the Bollinger Bands (€89.20 to €110.60), the stock is positioned at 59% of the range, showing no visible tension. The next technical threshold identified is at €109.60, with the current support at €88.80. The next financial calendar event is the release of the first quarter 2026 results, scheduled for June 1.
